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Objectives: Lower urinary tract symptoms (LUTS) and sexual dysfunction (SDys) are common problems
that affect quality of life (QOL) in elderly men. In addition to prescribed drugs, many over-the-counter
medications including supplements are used to treat QOL diseases. Phosphodiesterase inhibitors are
reported to be effective for both LUTS and SDys by increasing nitric oxide levels. French maritime pine
bark extract Pycnogenol®, which is a potent nitric oxide donor, is reported to be effective for SDys.
However, no reports have been published on whether it ameliorates LUTS.
Design: Open-labeled, randomized study. The effects of two supplements, Nokogiriyashi EX® containing
160 mg saw palmetto (SP) extract per tablet and Edicare® containing 10 mg of Pycnogenol®, 115 mg of L-
arginine and 92 mg of aspartate (PAA) per tablet on International Prostate Symptom Score (IPSS), IPSS
eQOL, Overactive Bladder Symptom Score (OABSS), International Index of Erectile Function 5 (IIEF5),
Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), urinary 8-OHdG and uroﬂowmetry
(UFM) of total 40 men with LUTS and SDys were examined.
Results: 19 subjects were instructed to take two tablets of SP, on the other 20 were on four tablets of PAA
for 16 weeks. IPSS and IPSSeQOL showed statistically signiﬁcant improvements in both groups. OABSS
and IIEF5 were signiﬁcantly improved in the PAA group. Conversely, ICIQ-SF, 8-OHdG and UFM did not
change in either group.
Conclusions: PAA might be an effective therapeutic alternative for elderly patients with LUTS and SDys.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of benign prostatic hyperplasia (BPH) gradually
increases with age, and the disease results in both lower urinary
tract syndromes (LUTS) and sexual dysfunction (SDys).1 The treat-
ment options for LUTS range from behavioral modiﬁcations, such as
bladder training, to medical treatment. Alpha-1 blockers and 5-Dokkyo Medical University
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ons.org/licenses/by-nc-nd/4.0/).alpha-reductase (5AR) inhibitors are the most frequently pre-
scribed drugs, but they can also cause SDys.2
Preparations made from the berries of saw palmetto (SP)
(Serenoa repens) have a long history of use in the treatment of LUTS
and SDys.3e7 Reported modes of action include inhibition of 5AR
and anti-inﬂammatory activities, as well as inhibition of autono-
mous receptors in the lower urinary tract.7 On the other hand,
clinical studies have reported that the proprietary, patented com-
bination of L-arginine aspartate and French maritime pine (Pinus
pinaster) bark extract Pycnogenol® might improve mild to moder-
ate SDys.8 Pycnogenol® consists of a concentrate of polyphenols
and acts to improve SDys by increasing nitric oxide production and
promoting vasodilation.8e11 However, there is no reports on the
clinical assessment of supplements containing of Pycnogenol®, L-
arginine, aspartic acid (PAA) for LUTS accompanied by SDys.
In the present study, we attempted to determine the efﬁcacy
and safety of a supplement containing PAA for elderly patients withrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
Table 1
Backgrounds of participants.
SP PAA p-value
Age (years) 76.7 ± 6.9 76.1 ± 4.7 0.142
Height (cm) 168.3 ± 3.6 167.2 ± 4.9 0.177
Body weight (kg) 69.1 ± 8.9 68.3 ± 6.9 0.467
BMI (kg/m2) 23.8 ± 2.7 24.9 ± 2.3 0.267
P-EW (cc) 29.2 ± 8.4 31.1 ± 9.8 0.423
IPSS
Total 13.4 ± 5.5 14.5 ± 6.2 0.182
Storage 6.2 ± 2.5 8.1 ± 2.9 0.114
Voiding 7.3 ± 4.3 8.4 ± 4.3 0.974
QOL 4.0 ± 1.1 4.0 ± 0.9 0.228
OABSS 4.9 ± 2.5 6.8 ± 3.3 0.706
IIEF5 1.2 ± 0.5 1.4 ± 0.5 0.453
ICIQ-SF 1.9 ± 3.2 5.3 ± 4.9 0.197
UFM
RV (ml) 30.8 ± 22.3 36.4 ± 21.5 0.655
Qmax (ml/s) 13.3 ± 6.8 12.6 ± 6.7 0.187
8-OHdG (ng/mlCRE) 18.4 ± 8.2 17.4 ± 5.4 0.725
*p-value, estimated probability of rejecting the null hypothesis.
Notes: P-EW, prostate estimate weight; QOL, quality of life; OABSS, Overactive
Bladder Symptom Score; IPSS, International Prostate Symptom Score; IIEF5, 5-item
version of the International Index of Erectile Function; ICIQ-SF, Consultation on
Incontinence Questionnaire e-short Form; UFM, uroﬂowmetry; RV, residual urine
volume; Qmax, maximum ﬂow rate; 8OHdG, 8-hydroxy-2’-deoxyguanosine.
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2. Materials and methods
This study was conducted in compliance with the Helsinki
Declaration after approval was granted by the Ethics Committee of
Dokkyo Medical University Koshigaya Hospital. We obtained writ-
ten informed consent from all participants after thoroughly
explaining the efﬁcacy and possible adverse reactions of SP and
PAA.
Patients who consulted our hospital with LUTS and SDys be-
tween June 2013 and May 2014 were considered for enrollment.
The inclusion criteria were 1) male patients between 55e80 years
of age; 2) an International Prostate Symptom Score (IPSS) of 8 or
more; 3) the presence of LUTS for at least 2 months; and 4) the
presence of SDys (erectile dysfunction and/or decreased libido).
Exclusion criteria were 1) habitual consumption of a supplement
that is intended for the treatment of LUTS or SDys; 2) allergy to the
substances under investigation; 3) any complications that could
affect voiding function such as neurogenic bladder, urethral stric-
ture, and active urinary tract infection; 4) the existence of diabetes
mellitus, heart disease, renal disease, or hepatic disease. And all
participants were required to visit the outpatient clinic at the ﬁrst
visit, and after 4, 8 and 16 weeks.
The study was designed as an open, randomized, two-arm study
comparing the commercialized food supplement Nokogiriyashi
EX® (manufactured by Kobayashi Pharmaceutical Co., Ltd., and
containing 160 mg SP extract per tablet) and Edicare® (manufac-
tured by Kobayashi Pharmaceutical Co., Ltd., and containing 10 mg
of Pycnogenol®, 115 mg of L-arginine, and 92 mg of aspartic acid per
tablet).
Subjects had blood and urine samples collected, were asked
about their general health condition and examined by a physician
before the start of the study, and again at 8 and 16 weeks after the
study. In combination with the questioning by the physician: IPSS,
IPSS-Quality of Life (QOL), the 5-item version of the International
Index of Erectile Function (IIEF5), Consultation on Incontinence
Questionnaire-Short Form (ICIQ-SF), Overactive Bladder Symptom
Score (OABSS), height, body weight, BMI, uroﬂowmetry (UFM) and
prostate estimated weight measured by abdominal ultrasonogra-
phy were also recorded. Blood test parameters consisted of red
blood cell count, white blood cell count, hemoglobin, hematocrit,
platelet count, total protein, albumin, lactate dyhydrogenase (LDH),
alkaline phosphatase (ALP), aspartate amino transferase (AST),
alanine transaminase (ALT), total bilirubin, creatinine, urea nitro-
gen, hemoglobin Alc, triglycerides, total cholesterol, HDL choles-
terol, LDL cholesterol, sodium, potassium chlorine, and serum
prostaglandins. The pH, qualitative protein, qualitative glucose and
occult blood were investigated by urinalysis. As a marker of
oxidative stress, we evaluated urinary 8-OHdG levels using an ICR-
001 device (Techno Medica, Yokohama, Japan) according to the
manufacturer's recommendations.
Data are reported as means ± SD and were analyzed using SPSS
software version 12.0 (IBM, Chicago, IL). Wilcoxon signed-rank test
was used to evaluate the effects of treatment, and P < 0.05 was
considered signiﬁcant.
3. Results
3.1. Patients
Forty subjects were instructed to take two tablets of Nokogir-
iyashi EX® (SP 320 mg/day) or 6 tablets of Edicare® (Pycnogenol®
60mg/day) for 16 weeks. One subject in the SP groupwas unable tocontinue the study because of an adverse reaction (loose stool) and
was excluded from the analysis. Thus, 19 subjects (age range 68e80
years, mean 76.7 ± 6.9) in the SP group and 20 subjects (age range
67e80 years, mean 76.1 ± 4.7) in the PAA group (Table 1) were
examined. There were no signiﬁcant differences in clinical param-
eters between the two groups.3.2. Efﬁcancy
We found the following results in the SP group: 1) subjective
outcomes assessed by IPSS total, subscore (storage and voiding score)
and QOL were signiﬁcantly improved; 2) no signiﬁcant improve-
ments were observed in the other parameters (OABSS, IIEF5, ICIQ-SF,
UFM and 8-OHdG). On the other hand, the PAA group showed the
following results: 1) subjective outcomes assessed by IPSS total,
subscore (storage and voiding score), QOL, OABSS and IIEF5 were
signiﬁcantly improved; 2) no signiﬁcant improvements were
observed in the other parameters (ICIQ-SF, UFM and 8-OHdG)
(Table 2). Comparing PAA to SP group showed a signiﬁcant difference
regarding change from baseline of IIEF5 (Table 3). The other pa-
rameters (IPSS total, subscore, QOL, OABSS, ICIQ-SF, UFM and 8-
OHdG) did not showa signiﬁcant difference between the two groups.3.3. Blood and urine test
The baseline mean red blood cell count, white blood cell count,
hemoglobin, hematocrit, platelet count were all within normal
limits in both groups. At the end of the 16 weeks study period, the
difference of haematology results were not statistically different
(data not shown). Results of biochemistry markers indicated a
slight decrease in AST and HbA1c in the PAA group (data not
shown), but these changes were all within normal limits. Urinalysis
remained unchanged in both group at 8 and 16 weeks.3.4. Safty
Three patients reported 4 adverse events, including nausea,
loose stool and pruritus, all of which were mild in nature and seen
as related to the study medication. From the total of 40 patients,
Table 2
Effects of SP and PAA.
SP baseline After 16 weeks PAA baseline After 16 weeks
IPSS
Total 13.4 ± 5.5 9.6 ± 5.3 14.5 ± 6.2 10.4 ± 5.6
Storage 6.2 ± 2.5 4.4 ± 2.6 8.1 ± 2.9 4.4 ± 2.6
Voiding 7.3 ± 4.3 5.2 ± 4.1 8.4 ± 4.3 5.2 ± 4.1
QOL 4.0 ± 1.1 2.9 ± 1.3 4.0 ± 0.9 2.9 ± 1.3
OABSS 4.9 ± 2.5 3.9 ± 2.9 6.8 ± 3.3 3.9 ± 2.9
IIEF5 1.2 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 2.3 ± 1.4
ICIQ-SF 1.9 ± 3.2 1.6 ± 2.7 5.3 ± 4.9 2.9 ± 3.8
UFM
RV (ml) 30.8 ± 22.3 41.9 ± 43.2 36.4 ± 21.5 41.9 ± 43.2
Qmax (ml/s) 13.3 ± 6.8 12.3 ± 5.3 12.6 ± 6.7 12.3 ± 5.3
8-OHdG (ng/mlCRE) 18.4 ± 8.2 22.5 ± 20.8 17.4 ± 5.4 18.9 ± 5.4
Notes: IPSS, International prostate symptom score; QOL, quality of life; OABSS, Overactive Bladder Symptom Score; IIEF5, 5-item version of the International Index of Erectile
Function; ICIQ-SF, Consultation on Incontinence Questionnaire e-short Form; UFM, uroﬂowmetry; RV, residual urine volume; Qmax, maximum ﬂow rate; 8OHdG, 8-hydroxy-
20-deoxyguanosine.
Table 3
Change from baseline.
SP PAA p-value
IPSS
Total 3.8 ± 5.3 6.1 ± 4.8 0.536
Storage 1.7 ± 2.6 3.1 ± 2.6 0.414
Voiding 2.1 ± 3.8 2.7 ± 3.0 0.804
QOL 0.8 ± 1.4 0.9 ± 1.6 0.805
OABSS 1.2 ± 2.6 1.9 ± 2.8 0.724
IIEF5 0.2 ± 0.5 0.9 ± 1.1 0.047
ICIQ-SF 0.9 ± 3.8 2.4 ± 4.7 0.564
UFM
RV (ml) 0.5 ± 44.0 1.4 ± 31.1 0.892
Qmax (ml/s) 1.0 ± 5.3 0.3 ± 7.0 0.703
8-OHdG (ng/mlCRE) 1.0 ± 5.4 2.3 ± 5.7 0.232
Notes: IPSS, International prostate symptom score; QOL, quality of life; OABSS,
Overactive Bladder Symptom Score; IIEF5, 5-item version of the International Index
of Erectile Function; ICIQ-SF, Consultation on Incontinence Questionnaire e-short
Form; UFM, uroﬂowmetry; RV, residual urine volume; Qmax, maximum ﬂow rate;
8OHdG, 8-hydroxy-20-deoxyguanosine.
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loose stool and was excluded from the analysis.
4. Discussion
In the present study, we demonstrated that consumption of a
supplement of PAA combination taken for 16 weeks improved both
LUTS and SDys. Pycnogenol® reportedly improves erectile
dysfunction (ED) by activating endothelial nitric oxide synthase
(eNOS).8 Increases of nitric oxide are achievedwhen Pycnogenol® is
administered in combination with L-arginine, the substrate for
eNOS, which is suggested to be a physiological response secondary
to increased sexual activity.9 The rationale for Pycnogenol® dosage
was inferred from a similar study of Aoki et al (2012) that used a
similar PAA, we refered similar study of report of similar PAA
combination with Pycnogenol® 60 mg, which demonstrated a sig-
niﬁcant improvement of ED.11 However, results of improvement in
IIEF5 was smaller in comparisonwith other reports on the effects of
Pycnogenol®.10e12 This could be partially attributed to the smaller
dose of Pycnogenol® used in this study compared with other
studies. The clinical trial that reported successful treatment with
PAA involved 40 men between 25 and 45 years of age suffering
from mild ED.10 After treatment with 1.7 g L-arginine per day for
one month, only 5% of all patients experienced normal erections.
During a second month of treatment, 80 mg Pycnogenol® per day
was added to the arginine regimen and yielded a signiﬁcant
improvement, with 80% of patients showing normal erections. A
third month's treatment with L-arginine, together with anincreased amount of Pycnogenol® (120 mg per day), further
increased the number of patients with restored normal erectile
function. At the end of the trial, 37 patients, equivalent to 92.5% of
all participants, achieved normal erectile function. Moreover, the
other reason for the smaller improvement in IIEF5 was because of
the mean age of patients in that study. Patients were in their ﬁfties
compared to the mean age of 76.1 years in the present study.13
The results of this study showed that consumption of a sup-
plement of SP signiﬁcantly improved IPSS total, subscore of storage
and voiding, IPSS-QOL. SP have a long standing use in the treatment
of mild to moderate LUTS and ED.3e7 More than 30 controlled
clinical trials evaluating treatments for LUTS and SDys have
demonstrated long-term efﬁcacy.5e7 The plant, which is indigenous
to Florida, was ﬁrst used by white settlers in the United States not
only for treatment of LUTS but also a treatment for ED, to improve
testicular atrophy and sperm production.3,4 Regarding the mode of
action, a variety of mechanisms for SP have been proposed
including anti-androgenic effects (prevention against the body's
natural response to testosterone by inhibition of the 5AR), anti-
inﬂammatory and anti-proliferative effects, but none have been
conclusively proven.7 In a 2002 Cochrane meta-analysis of the ef-
ﬁciency of SP extracts for men with LUTS attributed to BPH, 21
clinical trials were identiﬁed. Compared to placebo, SP signiﬁcantly
reduced nocturia, increased self-rated improvement, and improved
peak uroﬂow.14 Adverse effects were infrequent. However, results
comparing PAA to SP group in this study demonstrated that change
from baseline of IIEF5 was signiﬁcantly improved in the PAA group.
Oxidative stress is reported to result in pathophysiological
conditions of the urinary bladder by damaging the urothelium and
sensitizing bladder afferent signaling.15 Previous studies have
shown that oxidative stress mediates capsaicin-sensitive c-ﬁbers to
induce bladder hyperactivity.16 Several investigators have shown
that Pycnogenol® enhances antioxidant systems and scavenges free
radicals.17,18 Therefore, we hypothesized that Pycnogenol® might
ameliorate pathophysiological conditions in the urinary bladder
and could be a possible therapy for cases of LUTS that are unre-
sponsive to a1-blockers or antimuscarinic drugs19,20 However, we
did not demonstrate the anti-oxidative effects of either supplement
in this study.
The major limitations of this study were the small number of
patients, lack of a placebo group, and the omission of urodynamic
data. The improvement of LUTS and SDys has a strong placebo
component, so the possibility of a placebo effect might be high. It
remains unclear whether a supplement containing PAA might be a
potential therapeutic alternative for elderly patients with LUTS and
SDys; therefore, a prospective placebo-controlled study should be
conducted in the near future.
H. Yagi et al. / Journal of Traditional and Complementary Medicine 7 (2017) 117e1201205. Conclusions
Edicare®, a supplement containing PAA might be an effective
potential therapeutic alternative for elderly patients with LUTS and
SDys. However, further clinical investigations by placebo control
studies are required to elucidate the precise mechanisms of this
supplement.
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